Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

4-Year arthritis drug study shows promise for kids

NCT ID NCT03769168

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of the drug secukinumab in children with two types of juvenile idiopathic arthritis: juvenile psoriatic arthritis and enthesitis related arthritis. Fifty-five children who had already completed a previous study continued treatment for up to 4 years. The goal was to see if the drug kept working and remained safe over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

55 people

The number who actually took part.

Started

Jun 2019

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Patients had to have participated in the core study CAIN457F2304 and completed the entire treatment period up to and including Week 104. * Patients had to be deemed by the investigator to benefit from continued secukinumab therapy. Key Exclusion Criteria: * Patients with plans for administration of live vaccines during the extension study period were excluded. * Patients taking any other concomitant biologic immunomodulating agent(s) except secukinumab were excluded. * Patients who were deemed not to be benefiting from the study treatment based on lack of improvement or worsening of their symptoms were excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Enthesitis related arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

enthesitis-related juvenile idiopathic arthritis juvenile idiopathic arthritis psoriasis-related juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Enthesitis related arthritis Juvenile psoriatic arthritis

Contacts and locations

Locations

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio, 45229, United States

  • Legacy Emanuel Research Hospital Portland

    Portland, Oregon, 97232, United States

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Hamburg, 22081, Germany

  • Novartis Investigative Site

    Saint Augustin, 53757, Germany

  • Novartis Investigative Site

    Genova, GE, 16147, Italy

  • Novartis Investigative Site

    Naples, 80131, Italy

  • Novartis Investigative Site

    Krakow, 31503, Poland

  • Novartis Investigative Site

    Moscow, 119991, Russia

  • Novartis Investigative Site

    Saint Petersburg, 194100, Russia

  • Novartis Investigative Site

    Voronezh, 394036, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620149, Russia

  • Novartis Investigative Site

    Panorama, Western Cape, 7500, South Africa

  • Novartis Investigative Site

    Cape Town, 7925, South Africa

  • Novartis Investigative Site

    Santiago de Compostela, Galicia, 15706, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Istanbul, Halkali, 34303, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, TUR, 34098, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, 34093, Turkey (Türkiye)

  • St Lukes Intermountain Research Center

    Boise, Idaho, 83702, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.